A liver-selective LXR inverse agonist that suppresses hepatic steatosis

Area of Science:

• Hepatology
• Pharmacology
• Molecular Biology

Background:

• Fatty liver disease, linked to obesity and type 2 diabetes, can progress to severe conditions like cirrhosis and liver cancer.
• Current treatments for fatty liver disease have limited effectiveness, necessitating new therapeutic approaches.
• Targeting hepatic lipogenesis and inflammation are potential strategies for managing non-alcoholic fatty liver disease.

Purpose of the Study:

• To develop and evaluate a novel, liver-selective synthetic LXR inverse agonist for treating non-alcoholic hepatosteatosis.
• To assess the efficacy of SR9238 in suppressing hepatic lipogenesis, inflammation, and lipid accumulation.

Main Methods:

• Development of a selective synthetic Liver X Receptor (LXR) inverse agonist, SR9238.
• Administration of SR9238 to a mouse model of diet-induced non-alcoholic hepatosteatosis.
• Assessment of SR9238's potency, liver specificity, and effects on hepatic and plasma parameters.

Main Results:

• SR9238 demonstrated high potency against LXRα and LXRβ (40-200 nM IC50).
• The compound effectively suppressed hepatic lipogenesis, inflammation, and lipid accumulation in mice.
• Unexpectedly, SR9238 treatment led to reduced plasma cholesterol levels in diet-induced obese mice.

Conclusions:

• Liver-selective LXR inverse agonists, such as SR9238, represent a promising therapeutic strategy for non-alcoholic fatty liver disease.
• SR9238's ability to reduce liver fat, inflammation, and potentially cholesterol warrants further investigation for clinical application.